Learning Tracks

The expansion of biosimilars has ushered in a transformative era for biologic therapies. Yet the long-term sustainability of the biosimilar market hinges on more than product availability. It requires coordinated clinical adoption, informed policy frameworks, and strategic utilization management across both health systems and pharmacy benefit structures.

This panel will examine the current state of biosimilar adoption through a clinical and policy lens, exploring how provider behavior, formulary and utilization management strategies, and regulatory evolution, including interchangeability, are shaping the future of biosimilar sustainability. Panelists will discuss actionable strategies to align incentives, improve education, and ensure equitable access to biosimilar therapies across care settings.

Participants:
Danielle Bryan, PharmD, CSP
Program Director, Trade Relations, Vanderbilt Specialty Pharmacy Services

Victoria Facchini, PharmD
Director, Medical Pharmacy Strategy, Prime Therapeutics

Sean McGowan
Senior Vice President, Biosimilars & Branded Oncology, Amneal Pharmaceuticals

Moderator: Michael Sargent
Senior Director, Policy, AAM